Recent Price Movement and Market Context
On 18 Dec 2025, Epigral’s share price touched Rs.1388.6, the lowest level recorded in the past year. This follows a three-day consecutive decline, during which the stock’s returns contracted by 3.06%. Despite this downward trend, Epigral marginally outperformed its sector by 0.3% on the day of the new low. The stock has been trading within a narrow range of Rs.11.45 recently, indicating limited intraday volatility amid the broader downtrend.
Epigral’s current price is positioned below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages. This technical positioning suggests a persistent bearish momentum over multiple time horizons.
In contrast, the broader market index, Sensex, opened flat but moved into negative territory, trading at 84,450.41 points, down 0.13% from the previous close. The Sensex remains close to its 52-week high of 86,159.02, just 2.02% away, and is supported by bullish moving averages with the 50-day average above the 200-day average. This divergence highlights the relative underperformance of Epigral compared to the broader market.
Long-Term Performance and Financial Indicators
Over the last year, Epigral’s stock price has declined by 29.54%, contrasting with the Sensex’s positive return of 5.33% during the same period. The stock’s 52-week high was Rs.2114.3, indicating a substantial gap between the peak and current price levels.
Financially, the company’s operating profit has shown a negative compound annual growth rate of 5.49% over the past five years, signalling challenges in sustaining growth. The latest quarterly results reveal a mixed picture: while interest expenses for the most recent six months stood at Rs.45.21 crores, reflecting a growth of 286.41%, the quarterly profit after tax (PAT) was Rs.51.22 crores, down by 52.6% compared to the average of the previous four quarters. Additionally, the operating profit to net sales ratio for the quarter was recorded at 22.53%, the lowest in recent periods.
Our current monthly pick, this Mid Cap from Automobile Two & Three Wheelers, survived rigorous evaluation against dozens of contenders. See why experts are backing this one!
- - Rigorous evaluation cleared
- - Expert-backed selection
- - Mid Cap conviction pick
Comparative Performance and Valuation Metrics
Epigral’s performance has lagged behind the BSE500 index over the last three years, one year, and three months, underscoring a consistent pattern of underperformance relative to a broad market benchmark. Despite this, the company exhibits certain financial strengths. Its return on capital employed (ROCE) stands at a robust 23.19%, indicating efficient use of capital in generating earnings.
The company’s debt servicing capacity is supported by a low Debt to EBITDA ratio of 1.34 times, suggesting manageable leverage levels. Furthermore, the enterprise value to capital employed ratio is 2.5, which is considered attractive and points to a valuation discount relative to peers’ historical averages.
Over the past year, while the stock price has declined by nearly 30%, the company’s profits have risen by 37.1%, reflecting a divergence between market valuation and earnings growth. The price/earnings to growth (PEG) ratio is 0.5, which may indicate that the market is pricing in slower growth or other concerns despite profit gains.
Shareholding and Sector Position
Epigral operates within the Specialty Chemicals industry and sector, where it faces competitive pressures and sector-specific dynamics. The majority shareholding is held by promoters, which often implies a stable ownership structure.
Despite the recent price decline, the stock’s relative performance against its sector and the broader market highlights the challenges it faces in regaining investor confidence and market momentum.
Holding Epigral from Specialty Chemicals? See if there's a smarter choice! SwitchER compares it with peers and suggests superior options across market caps and sectors!
- - Peer comparison ready
- - Superior options identified
- - Cross market-cap analysis
Summary of Key Concerns and Market Positioning
The recent decline to Rs.1388.6 marks a significant low point for Epigral’s stock price within the last 52 weeks. The stock’s position below all major moving averages and its underperformance relative to both the Sensex and BSE500 index reflect ongoing challenges in the company’s financial trajectory and market sentiment.
While the company demonstrates strong capital efficiency and manageable debt levels, the contraction in quarterly profits and the negative trend in operating profit growth over five years have contributed to the subdued market valuation. The divergence between profit growth and stock price performance over the past year further illustrates the complex dynamics influencing investor perception.
Epigral’s standing within the Specialty Chemicals sector and its promoter-led ownership structure provide context for its current market position. However, the stock’s recent price action and financial indicators suggest a cautious environment for the company’s shares.
Only Rs. 14,999 - Get MojoOne + Stock of the Week for 1 Year PLUS 18 Months FREE! Claim Your Free Year →
